Calidi Biotherapeutics, Inc. (CLDI) is an innovative clinical-stage biotechnology company based in San Diego, California, focused on developing cutting-edge immunotherapies for cancer treatment. Utilizing its proprietary platform of genetically modified oncolytic viruses, Calidi aims to selectively target cancer cells while enhancing the body’s immune response, positioning itself at the forefront of the immuno-oncology sector. With a robust pipeline of promising clinical trials, the company is committed to addressing significant unmet medical needs in oncology, thereby aiming to reshape the standards of cancer care and improve patient outcomes.

NYSE MKT

USA

HEALTHCARE

BIOTECHNOLOGY

4475 EXECUTIVE DRIVE, SAN DIEGO, CA, UNITED STATES, 92121

December

$7.97 Million

-$19.5 Million

4.139

0.36

$0.00

0.0%

1.083